Navigation Links
Breckenridge Pharmaceutical Announces Settlement of Actos® (Pioglitazone Hydrochloride) Patent Litigation
Date:5/16/2011

BOCA RATON, Fla., May 16, 2011 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced that Breckenridge and Synthon Pharmaceuticals, Inc. have reached an agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving patent litigation related to Pioglitazone Hydrochloride 15 mg, 30 mg and 45 mg tablets, a generic equivalent version of Actos®. Under the terms of the agreement, Takeda granted Breckenridge and Synthon a non-exclusive, royalty-free license to its U.S. patents covering Actos®, permitting launch of their generic-equivalent formulation of Actos® after first-filers of ANDAs with paragraph IV certifications exhaust their 180-day marketing exclusivity on February 13, 2013, or earlier under certain circumstances, subject to regulatory approval.

Breckenridge and Synthon signed a distribution and supply agreement on the product in late 2009 and have been working together on this product, including the settlement of the paragraph IV litigation.

Actos® had approximately $3.4 billion in brand sales for the twelve months ending December 31, 2009, according to IMS Health. Actos® is a once-daily oral prescription medication that, with diet and exercise, has been shown to be effective for the treatment of type 2 diabetes.

* Actos® is a registered trademark of Takeda Chemical Industries, Ltd.

About Breckenridge:

Breckenridge Pharmaceutical, Inc. is a privately-held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of generic prescription products in many therapeutic categories. The Breckenridge label is recognized by Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide. The company markets over 70 products in a variety of dosage forms including: Tablets, Capsules, Soft Gel Capsules, Liquids, Suspensions, and Powders.

www.bpirx.com

About Synthon:

Synthon Pharmaceuticals, Inc., with its U.S. headquarters and laboratories located in Research Triangle Park, North Carolina, markets generic drugs through partnerships with other leading pharmaceutical companies. Synthon currently holds several approved, or tentatively approved, drug applications and has a pipeline containing more than a dozen products that are expected to be filed with the FDA within the next few years. Synthon Pharmaceuticals, Inc. is part of the Synthon group, a global privately held specialty pharma company with offices, laboratories and manufacturing sites in 11 countries worldwide.

www.synthon.com


'/>"/>
SOURCE Breckenridge Pharmaceutical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Breckenridge Announces Approval of Anastrozole Tablets
2. Breckenridge Pharmaceutical to Market Methylphenidate Oral Solution Through Agreement With Tris Pharma (Monmouth Junction, NJ)
3. Breckenridge Pharmaceutical Enters Agreement with Oman Pharmaceutical Products Company LLC
4. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 24, 2017 The Board of Directors of ... Report 2016 including the complete 2016 Annual Accounts with notes. ... Nordic Nanovector,s website in the section Investor Relations/Reports and presentations/Annual ... ... Kvåle, Chief Financial Officer Cell: +47-91-51-95-76 Email: ir@nordicnanovector.com ...
(Date:3/23/2017)... Research and Markets has announced the addition ... Replacement Procedure By Technique, Repair Procedure By Technique, By Region, By ... ... forecasted to grow at a CAGR of 13.35% during 2016-2021 ... rising aging population, growth in population with heart disease and rising ...
(Date:3/23/2017)... , March 23, 2017 As ... years along with the prevalence of allergic diseases, ... measures are currently revolutionising the ways in which ... Allergies 2017 promises to be both a ... amongst the allergy interest groups, immunologists, research scholars ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Vighter established its NAEMT ... by providing Prehospital Trauma Life Support (PHTLS) course scholarships to four medics assigned ... education developed in cooperation with the American College of Surgeons to promote critical ...
(Date:3/24/2017)... ... March 24, 2017 , ... The Radiology Business Management Association (RBMA) ... annual awards, now in their 12th year, are among the most prestigious in radiology ... 2016, the awards were retooled to recognize achievements in both large budget (over $5,000) ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... and related services to families and business owners across eastern Michigan, is connecting ... regional families struggling with financial difficulties. , The Oxford/Orion FISH Food Pantry works ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... that they are now offering treatments for sleep apnea and TMJ at their ... Sleep apnea , specifically the obstructive type, is increasingly being treated at ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health (“GH”) ... prep patients for colonoscopy at the HyGIeaCare® Center that is to be located ... , The HyGIeaCare® Prep, cleared by the U.S. Food and Drug ...
Breaking Medicine News(10 mins):